{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:53:03Z","timestamp":1781527983133,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clbc.2026.04.016","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:16:01Z","timestamp":1777587361000},"page":"161-178.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Severe Adverse Events in Neoadjuvant Therapy of Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Phase 3 Trials"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1996-7428","authenticated-orcid":false,"given":"Marcelo","family":"Antonini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5973-623X","authenticated-orcid":false,"given":"Andr\u00e9","family":"Mattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9429-3067","authenticated-orcid":false,"given":"Marcelo","family":"Madeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7156-2890","authenticated-orcid":false,"given":"Francisco Pimentel","family":"Cavalcante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1643-727X","authenticated-orcid":false,"given":"Felipe Pereira","family":"Zerwes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0589-1423","authenticated-orcid":false,"given":"Fabricio Palermo","family":"Brenelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1860-6898","authenticated-orcid":false,"given":"Antonio Luis","family":"Frasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2113-6324","authenticated-orcid":false,"given":"Eduardo Camargo","family":"Millen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8947-2009","authenticated-orcid":false,"given":"Giuliano Tavares","family":"Tosello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7516-0215","authenticated-orcid":false,"given":"Marina Diogenes","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1418-0295","authenticated-orcid":false,"given":"Gil","family":"Facina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1629-3437","authenticated-orcid":false,"given":"Sabrina Monteiro","family":"Rondelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6216-6327","authenticated-orcid":false,"given":"Renata","family":"Arakelian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6162-9463","authenticated-orcid":false,"given":"Larissa Chrispim","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3607-619X","authenticated-orcid":false,"given":"Lucas M.","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4634-7619","authenticated-orcid":false,"given":"Patr\u00edcia Carvalho","family":"Baruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3789-4461","authenticated-orcid":false,"given":"Henrique Lima","family":"Couto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5246-4575","authenticated-orcid":false,"given":"Marina Fleury","family":"de Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2352-8719","authenticated-orcid":false,"given":"Rogerio","family":"Fenile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1211-2823","authenticated-orcid":false,"given":"Renata Montarroyos","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8401-3967","authenticated-orcid":false,"given":"Pedro Paulo de Andrade","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0120-6698","authenticated-orcid":false,"given":"Gabriela de Oliveira","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9448-6114","authenticated-orcid":false,"given":"Leonardo Ribeiro","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4145-8598","authenticated-orcid":false,"given":"Ruffo","family":"Freitas-Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9941-9191","authenticated-orcid":false,"given":"Luiz Henrique","family":"Gebrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2026.04.016_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2020.576964","article-title":"Racial disparities in triple negative breast cancer: a review of the role of biologic and non-biologic factors","volume":"8","author":"Prakash","year":"2020","journal-title":"Front Public Health"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.016_bib0002","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41523-025-00731-0","article-title":"Population-specific patterns in assessing molecular subtypes of young black females with triple-negative breast cancer","volume":"11","author":"Rajagopal","year":"2025","journal-title":"npj Breast Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.016_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/medicina57010062","article-title":"Triple negative breast cancer: a review of present and future diagnostic modalities","volume":"57","author":"Dass","year":"2021","journal-title":"Medicina"},{"issue":"20","key":"10.1016\/j.clbc.2026.04.016_bib0004","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clbc.2026.04.016_bib0005","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"17","key":"10.1016\/j.clbc.2026.04.016_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics14171875","article-title":"Triple-negative breast cancer: molecular particularities still a challenge","volume":"14","author":"Varzaru","year":"2024","journal-title":"Diagnostics"},{"issue":"4","key":"10.1016\/j.clbc.2026.04.016_bib0007","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","article-title":"The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings","volume":"5","author":"Helleday","year":"2011","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.016_bib0008","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1038\/s41467-025-59151-0","article-title":"Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II\/III trial","volume":"16","author":"Abraham","year":"2025","journal-title":"Nat Commun"},{"issue":"8014","key":"10.1016\/j.clbc.2026.04.016_bib0009","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41586-024-07384-2","article-title":"The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer","volume":"629","author":"Abraham","year":"2024","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.clbc.2026.04.016_bib0010","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-025-07675-w","article-title":"Body composition as a potential biomarker of recurrence risk in patients with triple-negative breast cancer","volume":"211","author":"De Vis","year":"2025","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"10.1016\/j.clbc.2026.04.016_bib0011","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.clbc.2026.04.016_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PLoS One"},{"issue":"9938","key":"10.1016\/j.clbc.2026.04.016_bib0013","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"The Lancet"},{"key":"10.1016\/j.clbc.2026.04.016_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2023.103577","article-title":"Real-world evidence of neoadjuvant chemotherapy for breast cancer treatment in a Brazilian multicenter cohort: correlation of pathological complete response with overall survival","volume":"72","author":"Antonini","year":"2023","journal-title":"Breast"},{"issue":"10","key":"10.1016\/j.clbc.2026.04.016_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2025.e43069","article-title":"Pathologic complete response and breast cancer survival post-neoadjuvant chemotherapy: a systematic review and meta-analysis of real-world data","volume":"11","author":"Antonini","year":"2025","journal-title":"Heliyon"},{"issue":"12","key":"10.1016\/j.clbc.2026.04.016_bib0016","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.clbc.2026.04.016_bib0017","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with Pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clbc.2026.04.016_bib0018","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","article-title":"Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study","volume":"33","author":"Gianni","year":"2022","journal-title":"Ann Oncol"},{"issue":"10257","key":"10.1016\/j.clbc.2026.04.016_bib0019","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.clbc.2026.04.016_bib0020","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.annonc.2022.07.1940","article-title":"Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response*","volume":"33","author":"Loibl","year":"2022","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.clbc.2026.04.016_bib0021","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with Immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.clbc.2026.04.016_bib0022","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2026.04.016_bib0023","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clbc.2026.04.016_bib0024","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.016_bib0025","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.clbc.2026.04.016_bib0026","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.clbc.2026.04.016_bib0027","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.annonc.2022.01.009","article-title":"Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.clbc.2026.04.016_bib0028","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djx258","article-title":"Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results","volume":"110","author":"Gluz","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.clbc.2026.04.016_bib0029","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clbc.2026.04.016_bib0030","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clbc.2026.04.016_bib0031","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.016_bib0032","article-title":"PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Syst Rev"},{"issue":"4","key":"10.1016\/j.clbc.2026.04.016_bib0033","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.clbc.2026.04.016_bib0034","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with Pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.016_bib0035","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1186\/s12885-023-11293-4","article-title":"Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis","volume":"23","author":"Cortes","year":"2023","journal-title":"BMC Cancer"},{"issue":"17_suppl","key":"10.1016\/j.clbc.2026.04.016_bib0036","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109","article-title":"Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1\u2013positive advanced triple-negative breast cancer (TNBC): primary results from the randomized phase 3 ASCENT-04\/KEYNOTE-D19 study","volume":"43","author":"Tolaney","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clbc.2026.04.016_bib0037","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"New Engl J Med"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:02:38Z","timestamp":1781524958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926000698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1526820926000698"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.04.016","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe Adverse Events in Neoadjuvant Therapy of Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Phase 3 Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}